biomodal, a leading omics-based life sciences technology and analytics company, has announced the launch of its Certified Service Provider (CSP) Program, a new global initiative aimed at expanding access to its duet multiomics sequencing technologies. The program brings together a network of internationally recognized research and service organizations that will deliver high-quality multiomic data to scientists and biopharma companies worldwide.
As demand for more comprehensive genomic and epigenomic insights accelerates, biomodal’s CSP network is designed to ensure consistent, high-standard access to its breakthrough duet evoC and duet +modC solutions — technologies that allow researchers to capture both genetic and epigenetic information from the same DNA molecule in a single workflow.
Expanding Global Access to Multiomic Insights
biomodal’s CSP program includes a network of carefully selected and trained service organizations across North America, Europe, and Asia-Pacific. Each Certified Service Provider undergoes rigorous training, standardization, and validation to ensure accuracy, reproducibility, and data quality that meet biomodal’s stringent benchmarks.
These certified centers will make duet multiomics technology more accessible to researchers working in critical areas such as cancer, neuroscience, cardiovascular disease, aging, and environmental genomics. The program also aims to accelerate translational research in disease detection, therapy selection and monitoring, and biomarker discovery — areas where multiomic analysis has become increasingly essential.
Among the first cohort of Certified Service Providers are several prominent institutions and research facilities:
- Eurofins Clinical Enterprise – Framingham, Massachusetts, USA
- Garvan Institute of Medical Research – Sydney, Australia
- Life & Brain GmbH – Bonn, Germany
- McGill Genome Center – Montreal, Quebec, Canada
- MOgene – St. Louis, Missouri, USA
- University of Michigan Medical School – Ann Arbor, Michigan, USA
- University of Minnesota Genomics Center – Minneapolis, Minnesota, USA
- Zymo Research – Irvine, California, USA
This diverse network reflects biomodal’s global vision: to empower researchers worldwide with the ability to generate richer, more integrated biological insights through unified sequencing data.
Duet Multiomics: Integrating the Genome and Epigenome
biomodal’s duet multiomics platform provides researchers with the ability to simultaneously profile the genetic (sequence) and epigenetic (modification) landscapes of DNA within a single experiment. Its flagship technologies — duet evoC and duet +modC — enable 5-base and 6-base sequencing, capturing canonical bases (A, T, C, G) alongside epigenetic modifications such as 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC).
This approach provides a more holistic view of gene regulation, cellular identity, and disease mechanisms, surpassing the limitations of traditional sequencing that often examines genetic or epigenetic layers in isolation.
Researchers are already applying duet multiomics to a broad range of scientific areas, from oncology and neuroscience to aging and cardiovascular health, and even in environmental studies examining the impact of climate change on species development.
“This technology offers a more complete picture of biology and gene regulation in cancer, aging, and cardiovascular health — and can even unlock an understanding of the effects of climate change on species development,” said Dr. Orion Tong, R&D Lead at the Garvan Genomics Platform in Sydney.
Leading Institutions Embrace biomodal’s Multiomics Revolution
The launch of the CSP program has been met with enthusiasm from biomodal’s early partners, many of whom have already begun deploying duet technology in their research and service offerings.
“Our partnership with biomodal puts cutting-edge multiomic tools directly into the hands of scientists,” said Dr. Keith Booher, Services Director at Zymo Research Corporation. “The ability to profile 5mC, 5hmC, and the four canonical bases in one workflow is a transformative step for understanding disease biology — it’s truly changing the game.”
Dr. Per Hoffmann, Chief Commercial Officer at Life & Brain GmbH, emphasized the added scientific depth the partnership provides: “With biomodal’s duet multiomics solutions, we deliver transformative insights by generating and analyzing the 5-base and 6-base genome. This partnership enables us to continuously provide innovative services that deepen understanding of normal and disease biology and enable better identification of disease-relevant biomarkers.”
At McGill Genome Center, researchers have been among the first to integrate biomodal’s technology into their sequencing workflows.
“As early adopters of the 5-base and 6-base solutions from biomodal, we are excited to share that we are now officially a Certified Service Provider,” said Ioannis Ragoussis, Head of Genome Sciences at McGill Genome Center. “This milestone enables us to support more advanced research and deliver greater depth of mechanistic understanding to the researchers we serve.”
Similarly, Claudia Lalancette, Director of the University of Michigan Epigenomics Core Lab, noted how duet’s unique capabilities are transforming genomic science:
“We continually evaluate the most advanced technologies for our research community. biomodal’s 6-base solution opens new frontiers in genetics and epigenetics, revealing insights that were previously out of reach.”
A Milestone for biomodal and the Broader Research Community
The CSP initiative marks a major milestone in biomodal’s mission to democratize access to advanced multiomics technologies. By working with elite research institutions and service providers, biomodal aims to standardize data quality across the global research ecosystem while providing a competitive advantage to its partners.
“We are excited to extend the novel benefits of our duet multiomics solutions by partnering with leaders in the life sciences community to better support our customers worldwide,” said Peter Fromen, CEO of biomodal. “Our CSP program provides a competitive advantage to service providers and helps ensure that their customers receive the highest quality multiomic data using biomodal technology.”
Through the CSP network, biomodal is not only expanding the reach of its duet solutions but also helping to shape the next generation of multiomic research — one that integrates genetic and epigenetic information to uncover a deeper, more dynamic understanding of biology.
